Theravance Retained Earnings vs Deferred Long Term Liab Analysis
TBPH Stock | USD 8.98 0.14 1.54% |
Theravance Biopharma financial indicator trend analysis is much more than just breaking down Theravance Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theravance Biopharma is a good investment. Please check the relationship between Theravance Biopharma Retained Earnings and its Deferred Long Term Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.
Retained Earnings vs Deferred Long Term Liab
Retained Earnings vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theravance Biopharma Retained Earnings account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Theravance Biopharma's Retained Earnings and Deferred Long Term Liab is -0.68. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Theravance Biopharma, assuming nothing else is changed. The correlation between historical values of Theravance Biopharma's Retained Earnings and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Theravance Biopharma are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Retained Earnings i.e., Theravance Biopharma's Retained Earnings and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | -0.68 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from Theravance Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theravance Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.As of now, Theravance Biopharma's Sales General And Administrative To Revenue is increasing as compared to previous years.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 293.0M | 130.5M | 110.7M | 105.2M | Cost Of Revenue | 7.3M | 6.6M | 6.1M | 5.7M |
Theravance Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Theravance Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Theravance Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 55.6M | 62.3M | 69.5M | 73.6M | 55.3M | 53.3M | |
Total Assets | 408.8M | 469.1M | 374.8M | 607.4M | 382.0M | 418.6M | |
Other Current Liab | 57.8M | 76.1M | 37.9M | (1.6M) | 24.8M | 40.9M | |
Total Current Liabilities | 111.7M | 123.6M | 58.6M | 28.7M | 24.8M | 23.5M | |
Other Liab | 28.0M | 2.2M | 2.7M | 91.5M | 105.2M | 110.5M | |
Accounts Payable | 4.8M | 6.8M | 3.1M | 1.6M | 1.5M | 1.4M | |
Other Assets | 6.1M | 3.3M | 4.1M | 201.9M | 232.2M | 243.8M | |
Inventory | 0.0 | 1.0 | 20.4M | 10.2M | 1.5M | 0.95 | |
Other Current Assets | 7.1M | 10.4M | 8.6M | 7.7M | 13.6M | 8.4M | |
Total Liab | 632.7M | 772.8M | 713.4M | 165.6M | 169.0M | 160.6M | |
Property Plant Equipment | 12.6M | 16.4M | 53.3M | 11.9M | 13.7M | 16.5M | |
Total Stockholder Equity | (223.8M) | (303.8M) | (338.6M) | 441.8M | 213.0M | 223.6M | |
Net Tangible Assets | (169.4M) | 116.7M | (338.6M) | 577.0M | 519.3M | 545.3M | |
Property Plant And Equipment Net | 59.2M | 59.7M | 53.3M | 52.0M | 45.4M | 33.1M | |
Current Deferred Revenue | 31.6M | 11.5M | 98K | 24K | (5.4M) | (5.2M) | |
Retained Earnings | (1.2B) | (1.5B) | (1.7B) | (853.9M) | (909.1M) | (954.6M) | |
Cash | 58.1M | 81.5M | 90.0M | 298.2M | 39.5M | 37.6M | |
Non Current Assets Total | 70.3M | 75.7M | 124.9M | 253.9M | 248.5M | 260.9M | |
Non Currrent Assets Other | 6.1M | 3.3M | 4.1M | 201.1M | 202.3M | 212.4M | |
Long Term Debt | 454.4M | 445.2M | 227.0M | 599.4M | 689.3M | 723.8M | |
Net Receivables | 50.6M | 69.7M | 57.6M | 16.8M | 17.5M | 27.9M | |
Short Term Investments | 222.8M | 211.5M | 83.5M | 29.3M | 62.9M | 112.2M | |
Liabilities And Stockholders Equity | 408.8M | 469.1M | 374.8M | 607.4M | 382.0M | 454.6M | |
Non Current Liabilities Total | 521.0M | 649.2M | 654.8M | 136.9M | 144.2M | 137.0M | |
Long Term Investments | 49.8M | 11.9M | 8.7M | 12.8M | 67.5M | 0.0 | |
Property Plant And Equipment Gross | 59.2M | 16.4M | 53.3M | 52.0M | 66.9M | 70.3M | |
Total Current Assets | 338.5M | 393.3M | 249.9M | 353.5M | 133.5M | 126.9M | |
Accumulated Other Comprehensive Income | 145K | 47K | 0.0 | (15K) | (65K) | (68.3K) | |
Net Debt | 434.9M | 565.6M | 562.1M | (224.1M) | 5.7M | 5.4M | |
Cash And Short Term Investments | 280.8M | 292.9M | 173.5M | 327.5M | 102.4M | 97.3M | |
Retained Earnings Total Equity | (1.2B) | (1.5B) | (1.7B) | (853.9M) | (768.5M) | (806.9M) | |
Capital Surpluse | 1.0B | 1.2B | 1.4B | 1.3B | 1.5B | 1.1B | |
Other Stockholder Equity | 1.0B | 1.2B | 1.4B | 1.3B | 1.1B | 1.1B | |
Non Current Liabilities Other | 21.3M | 1.8M | 2.7M | 1.7M | 33.7M | 35.4M | |
Short Long Term Debt Total | 492.9M | 647.1M | 652.1M | 74.1M | 45.2M | 43.0M | |
Long Term Debt Total | 454.4M | 445.2M | 227.0M | 228.0M | 262.2M | 330.2M |
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 1.191 | Quarterly Revenue Growth 0.392 | Return On Assets (0.06) | Return On Equity (0.16) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.